Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | CCNC | P24863 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979642 | 0.90 | HTT (0.89) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL16178483 | 0.86 | HTT (0.65) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL417569 | 0.86 | RAB9A (1.00) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL20237168 | 0.85 | HTT (0.80) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL20236314 | 0.85 | HTT (0.80) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL28647113 | 0.85 | HTT (0.56) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL31058115 | 0.84 | HTT (0.54) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL20236298 | 0.84 | HTT (0.78) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL5426206 | 0.84 | HTT (0.78) | HTTRAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL5458965 | 0.83 | MAPT (0.79) | RAB9ANPC1SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1812790-A | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor | WYETH CORP (US) | 2006-08-02 | — | — | CN | claimed |
| CN-108137518-A | As 6 inhibitor of histone deacetylase 1,3,4- oxadiazole derivatives compound and include its pharmaceutical composition | 株式会社钟根堂 | 2018-06-08 | — | — | CN | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HTT 1394/4885RAB9A 3597/4885NPC1 804/4885 |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | HTT 3659/4885RAB9A 3880/4885NPC1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.